We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $11.1B
1-Year Est. Return 207.82%
This Fund
S&P 500
This Quarter Est. Return
+33.35%
1 Year Est. Return
+207.82%
3 Year Est. Return
+512.05%
5 Year Est. Return
+1,035%
10 Year Est. Return
+45,230.58%
AUM
$2.6B
AUM Growth
+$504M
Cap. Flow
+$116M
Cap. Flow %
4.45%
Top 10 Hldgs %
62.82%
Holding
68
New
12
Increased
10
Reduced
11
Closed
26

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$90.4M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$86M
3
PTCT icon
PTC Therapeutics
PTCT
+$71.6M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$69.4M
5
SPPI
Spectrum Pharmaceuticals Inc
SPPI
+$63.4M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$83.4M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$48.5M
3
ARMO
ARMO BioSciences, Inc. Common Stock
ARMO
+$45.2M
4
DVAX
Dynavax Technologies
DVAX
+$32.8M
5
ARRY
Array Biopharma Inc
ARRY
+$31.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.69%
2 Miscellaneous 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KPTI icon
51
Karyopharm Therapeutics
KPTI
$37M
– –
-37,377
Closed -$7.52M
MGNX icon
52
CALL
MacroGenics
MGNX
$260M
– –
-14,500
Closed -$72K
QURE icon
53
uniQure
QURE
$3.01B
– –
-67,758
Closed -$1.59M
SLDB icon
54
Solid Biosciences
SLDB
$894M
– –
-18,333
Closed -$2.06M
TNDM icon
55
Tandem Diabetes Care
TNDM
$1.16B
– –
-783,910
Closed -$3.89M
VCYT icon
56
Veracyte
VCYT
$3.27B
– –
-119,680
Closed -$665K
VRAY
57
DELISTED
ViewRay, Inc.
VRAY
– –
-730,161
Closed -$4.04M
JNCE
58
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
– –
-523,174
Closed -$11.7M
VIVE
59
DELISTED
VIVEVE MED INC
VIVE
– –
-1,533
Closed -$5.61M
GBT
60
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-152,000
Closed -$1.44M
STML
61
DELISTED
Stemline Therapeutics, Inc.
STML
– –
-524,321
Closed -$8.02M
AVEO
62
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
– –
-323,189
Closed -$9.37M
DOVA
63
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
– –
-125,000
Closed -$3.39M
ARRY
64
DELISTED
Array Biopharma Inc
ARRY
– –
-1,922,655
Closed -$31.4M
ARMO
65
DELISTED
ARMO BioSciences, Inc. Common Stock
ARMO
– –
-1,207,500
Closed -$45.2M
ONSIZ
66
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
– –
-233,333
Closed -$12K
AVXS
67
DELISTED
AveXis, Inc. Common Stock
AVXS
– –
-675,262
Closed -$83.4M
1 2
3

Similar funds

GI
GAMCO Investors Greenwich, Connecticut $11.1B AUM 41.79% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
BEI
Benjamin Edwards Inc Clayton, Missouri $11B AUM 18.22% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.05% 1-Year Est. Return
LCAM
London & Capital Asset Management London, United Kingdom $10.9B AUM 39.88% 1-Year Est. Return

Avoro Capital Advisors's Q2 2018 Portfolio in Review

As of Q2 2018, Avoro Capital Advisors held 68 positions worth $2.6B, up 24% from $2.09B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Avoro Capital Advisors deployed $116M of net new capital in Q2 2018, opening 12 new positions and adding to 10 existing holdings. Its largest new stake was Sarepta Therapeutics: 958,928 shares worth $127M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Global Blood Therapeutics, Inc., an estimated $48.5M trimmed.

  • Avoro Capital Advisors's largest Q2 2018 buy was Sarepta Therapeutics: 958,928 shares worth $127M.
  • Avoro Capital Advisors added most to Immunomedics Inc in Q2 2018, an estimated $15.6M increase.
  • Avoro Capital Advisors's biggest Q2 2018 reduction was Global Blood Therapeutics, Inc., cutting an estimated $48.5M.
  • Avoro Capital Advisors fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $83.4M.
  • Avoro Capital Advisors's ten largest holdings make up 63% of its $2.6B portfolio in Q2 2018.
  • Avoro Capital Advisors opened 12 new positions and closed 26 in Q2 2018.
  • Avoro Capital Advisors's portfolio value rose 24% quarter-over-quarter to $2.6B.

Based on Avoro Capital Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.